Based on patient data from prior genomic analysis of the tumor, KRAS mutated patients had a higher number of HD-CTCs/mL (p = 0.0210, median = 18.56, range = 0.00–968.70, mean = 139.87) in pre-resection draws than patients with the KRAS wild type (p = 0.0210, median = 0, range = 0.00–37.52, mean = 5.56). The gene discussed is KRAS; the disease is neoplasm.